Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure

doi:10.4330/wjc.v16.i8.448

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (129)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-1)

Sum=104

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=13

Publishing Process of This Article

Item

Count

Browse

Download

Sum=2

Aug 26, 2024 (publication date) through Aug 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Cardiol. Aug 26, 2024; 16(8): 448-457
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.448

Full Size Figure Download Figure

Figure 1 Mean change in high-sensitivity C-reactive protein concerning treatment group and baseline high sensitivity C-reactive protein level. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: hsCRP: High-sensitivity C-reactive protein; Sodium-dependent glucose transporters inhibitors.

Citation: Grubić Rotkvić P, Rotkvić L, Đuzel Čokljat A, Cigrovski Berković M. Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure. World J Cardiol 2024; 16(8): 448-457
URL: https://www.wjgnet.com/1949-8462/full/v16/i8/448.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i8.448